- Boston Scientific beats earnings expectations with significant year-over-year revenue growth.
- Analysts predict substantial upside potential for BSX with a target price of $116.34.
- GF Value suggests a cautious outlook with a lower fair value estimate.
Boston Scientific Corp (BSX, Financial) has reported an impressive performance in the first quarter, successfully surpassing market expectations. The company announced a non-GAAP earnings per share of $0.75, which is $0.08 higher than what analysts had anticipated. Additionally, Boston Scientific achieved a notable revenue of $4.66 billion, reflecting a robust 20.9% increase from the previous year, and beating revenue estimates by $90 million. Looking ahead, the company projects a reported sales growth between 15% and 17% for the full year 2025.
Expert Opinions from Wall Street Analysts
Wall Street analysts maintain a positive outlook on Boston Scientific Corp (BSX, Financial). Based on one-year price targets from 30 analysts, the average target price is set at $116.34, with estimates ranging from a high of $130.00 to a low of $84.11. This average target signifies a potential upside of 22.40% from the current trading price of $95.05. Investors can explore more detailed estimate data on the Boston Scientific Corp (BSX) Forecast page.
In terms of brokerage recommendations, Boston Scientific Corp (BSX, Financial) is currently rated with an average recommendation of 1.8, implying an "Outperform" status. This assessment comes from 34 brokerage firms and uses a rating scale from 1 to 5, where 1 denotes a Strong Buy and 5 indicates a Sell.
GuruFocus Analysis
According to GuruFocus estimates, the GF Value for Boston Scientific Corp (BSX, Financial) in one year is calculated to be $76.94. This implies a potential downside of 19.05% from the current price of $95.05. The GF Value is GuruFocus' assessment of the stock's fair trading value, derived from historical trading multiples, past business growth, and future performance forecasts. For more comprehensive analysis, visit the Boston Scientific Corp (BSX) Summary page.
